Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

The world's first reverse aging drug, ER-100, was injected into a human on June 9, 2026 The post The World’s First ...

The approach relies on “reprogramming” cells to a younger state. It’s one of many strategies being explored by biotech ...

Test time has arrived: the first person has been treated in a highly anticipated gene therapy trial that aims to coax aged ...

First human receives reverse-aging gene therapy in groundbreaking trial targeting glaucoma, using cellular reprogramming to ...

The experimental treatment, known as ER-100, is being tested in patients suffering from glaucoma and other forms of ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...